UBS Maintains Neutral on Bristol-Myers Squibb, Raises Price Target to $54
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Trung Huynh maintains a Neutral rating on Bristol-Myers Squibb (NYSE:BMY) but raises the price target from $50 to $54.

October 09, 2024 | 10:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
UBS analyst Trung Huynh maintains a Neutral rating on Bristol-Myers Squibb but raises the price target from $50 to $54, indicating a slightly more positive outlook.
The increase in the price target from $50 to $54 suggests a slightly more optimistic view on Bristol-Myers Squibb's stock performance, which could lead to a positive short-term impact on the stock price. However, the Neutral rating indicates that the analyst does not expect significant outperformance.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100